Differential mobility spectrometry followed by tandem mass spectrometry with multiple ion monitoring for bioanalysis of eptifibatide in rat plasma


    loading  Checking for direct PDF access through Ovid

Abstract

HighlightsCombining differential mobility spectrometry with MIM for quantitation of eptifibatide in rat plasma.Using differential mobility spectrometry to reduce the background noise to achieve a higher S/N ratio.The method was successfully applied to pharmacokinetic study of eptifibatide in Wistar rats.Eptifibatide is a therapeutic cyclic peptide with poor collision-induced dissociation (CID) efficiency for multiple reaction monitoring (MRM), which limits the development of a traditional liquid chromatography-tandem mass spectrometry (LC–MS/MS) bioassay with MRM. In this study, a method combining differential mobility spectrometry (DMS) with liquid chromatography-multiple ion monitoring (LC-DMS-MIM) was developed for the quantitation of eptifibatide in rat plasma. After solid phase extraction (SPE) of 100 μL plasma on an Oasis® HLB cartridge, the analyte and I.S. (octreotide) were analyzed using a SCIEX QTRAP 6500 operated in the positive ion mode and preceded by a DMS device. The lower limit of quantitation (LLOQ) for eptifibatide was 0.5 ng/mL using only 100 μL plasma. The method was linear in the concentration range 0.5–300 ng/mL with good precision and accuracy. Compared to regulated quantitative LC–MS/MS bioanalysis of eptifibatide, the LC-DMS-MIM method effectively overcomes the sensitivity challenge in the LC-MRM method and reduces the high background noise and matrix interference in LC-MIM method without DMS. The method was successfully applied to a pharmacokinetic study involving intravenous injection of eptifibatide to Wistar rats.

    loading  Loading Related Articles